Xiao Z, McCallum T J, Brown K M, Miller G G, Halls S B, Parney I, Moore R B
Department of Experimental Surgery, University of Alberta, Edmonton, Canada.
Br J Cancer. 1999 Oct;81(4):638-46. doi: 10.1038/sj.bjc.6690741.
An animal tumour model that mimics the human counterpart is essential for preclinical evaluation of new treatment modalities. The objective of this study was to develop and characterize such a model. To accomplish this, the established AY-27 rat bladder transitional cell carcinoma (TCC) cell line was transplanted orthotopically into Fischer CDF344 female rats. AY-27 TCC cells were grown in monolayer cell culture and instilled intravesically as single cell suspensions into bladders that had been conditioned with mild acid washing. Tumour growth was assessed weekly by subjecting the rats to magnetic resonance imaging (MRI). At intervals following implantation and MRI tumour detection, the animals were sacrificed for necropsy, histological examination and immunocytochemical studies. Flow cytometry was also performed for detection of Fas or Fas-ligand expression on AY-27 cells. The overall tumour establishment was 95% (97/102 rats) at 12-50 days, while in a subgroup of animals sacrificed at 16 days, 80 out of 82 animals (97%) developed TCC, the majority of which was superficial. Tumour stage was assessed by gross pathology and light microscopy. Histological examination of the tumour specimens confirmed the presence of grade II-III TCC. Immunocytochemistry confirmed that the tumour model maintained the features of TCC. The changes seen on MRI correlated well with the extent of tumour invasion identified histologically. Patchy carcinoma in situ could be detected histologically 12-13 days post-inoculation, and progressed to papillary tumour or invasive disease thereafter. Neither Fas nor Fas-ligand was expressed on AY-27 cells. The orthotopic AY-27 TCC model is highly reproducible and is ideal for preclinical studies on experimental intravesical therapies.
一种能模拟人类肿瘤的动物肿瘤模型对于新治疗方式的临床前评估至关重要。本研究的目的是开发并表征这样一种模型。为实现这一目标,将已建立的AY - 27大鼠膀胱移行细胞癌(TCC)细胞系原位移植到Fischer CDF344雌性大鼠体内。AY - 27 TCC细胞在单层细胞培养中生长,并作为单细胞悬液经膀胱内灌注到经轻度酸洗预处理的膀胱中。每周通过对大鼠进行磁共振成像(MRI)来评估肿瘤生长情况。在植入和MRI检测到肿瘤后,定期处死动物进行尸检、组织学检查和免疫细胞化学研究。还进行了流式细胞术检测AY - 27细胞上Fas或Fas配体的表达。在12 - 50天,总体肿瘤形成率为95%(97/102只大鼠),而在16天处死的一组动物中,82只动物中有80只(97%)发生了TCC,其中大多数为浅表性。通过大体病理学和光学显微镜评估肿瘤分期。肿瘤标本的组织学检查证实存在II - III级TCC。免疫细胞化学证实该肿瘤模型保留了TCC的特征。MRI上观察到的变化与组织学确定的肿瘤浸润程度密切相关。接种后12 - 13天组织学上可检测到局灶性原位癌,此后进展为乳头状肿瘤或浸润性疾病。AY - 27细胞上既不表达Fas也不表达Fas配体。原位AY - 27 TCC模型具有高度可重复性,是实验性膀胱内治疗临床前研究的理想模型。